Paul Lama, MD
Glaucoma Specialist · Rochelle Park, NJNPI 1033130315
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Glaukos Corporation at 44.1% of the total. Reporting peaked in 2020 at $13,931 and has fallen 51.2% since, to $6,795 in 2025.
Across 251 payments — averaging $287.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$32K
- Aerie Pharmaceuticals, Inc.$29K
- Alcon$8K
- AbbVie$2K
- NEW World Medical,inc.$496
- Bausch & Lomb Americas Inc.$379
- plus $500 from 10 others
What the payments were for
- Consulting fees$24,96835%
- Speaking & faculty fees$36,75651%
- Travel & lodging$2,5864%
- Food & beverage$7,79911%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 37 | $31,860 |
| Aerie Pharmaceuticals, Inc. | 49 | $29,426 |
| Alcon | 17 | $7,720 |
| AbbVie(2 entities) | 95 | $1,808 |
| NEW World Medical,inc. | 8 | $496 |
| Bausch & Lomb Americas Inc. | 14 | $379 |
| Oyster Point Pharma, Inc. | 8 | $134 |
| Thea Pharma Inc. | 7 | $124 |
| Sight Sciences, Inc. | 4 | $60 |
| Amgen | 3 | $50 |
| Novartis | 3 | $40 |
| Sun Pharmaceutical Industries Inc. | 2 | $33 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Biotissue Holdings Inc. | 1 | $14 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $14 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$36,334
- Rocklatan$36,334
- iStent inject W$4,459
- iStent inject Trabecular Micro-Bypass Stent System$3,380
- iDose$2,585
- iStent$2,500
- iStent Trabecular Micro-Bypass Stent System$2,249
- Photrexa$424
- IACCESS$298
- KXL System$160
- iDoseTR$152
- XEN GLAUCOMA TREATMENT SYSTEM$148
- enVista MX60 IOL$147
- Kahook Dual Blade$121
- Streamline Surgical System$121
- Ahmed Glaucoma Valve$121
How this compares
Too few glaucoma specialist providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 438 | $233,472 |
| RhopressaNetarsudil Mesylate | 280 | $134,484 |
| CombiganBrimonidine Tartrate/Timolol | 208 | $92,835 |
| Alphagan PBrimonidine Tartrate | 194 | $81,410 |
| RocklatanNetarsudil Mesylat/Latanoprost | 141 | $77,398 |
| RestasisCyclosporine | 31 | $48,739 |
| Brimonidine Tartrate | 571 | $43,581 |
| VyzultaLatanoprostene Bunod | 85 | $41,609 |
| Travoprost | 168 | $26,314 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 79 | $24,321 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,184 | $24,132 |
| AzoptBrinzolamide | 47 | $23,798 |
| Pilocarpine Hcl | 318 | $23,467 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 98 | $20,031 |
| Timoptic OcudoseTimolol Maleate/Pf | 19 | $18,437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $1,808 | $456,456871 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $29,426 | $211,882421 claims |
| AlconSimbrinza, Azopt | $7,720 | $48,118126 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $379 | $41,60985 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $14 | $10,94830 claims |
| NovartisTravatan Z | $40 | $8,84019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Rochelle Park
- Linda HuangRochelle Park$50K
- Alice WilliamsVineland$8K
- Jessica ScottEast Orange$8K
- Matthew HoslerRahway$7K
- Gregory KramerWestfield$2K
- Sze WongOld Bridge$2K
- Omar Mobin-UddinNew Brunswick$1K
- Miriam HabielNewark$1K
- Khelly SavantClifton$774
- Linda ZhangWarren$610
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.